GlassScriptPhysician profile
Shonda T Bowers
NPI 1205182359
$1,179.87
in general payments reported to CMS, 2019-2025
24 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $163 · 2023: $82.26 · 2024: $19.78 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $223.92 | 2022-2025 | |
| Novo Nordisk INC | $173.14 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $97.09 | 2021-2025 | Verquvo |
| Lilly USA, LLC | $84.33 | 2025 | Jardiance, Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $65.49 | 2025 | Zenpep |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.20 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.12 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $40.80 | 2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $39.81 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.32 | 2025 | Xifaxan |
| Lundbeck LLC | $32.16 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $30.42 | 2021 | |
| Xeris Pharmaceuticals, INC. | $25.98 | 2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $24.35 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $24.01 | 2025 | Hetlioz, Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $21.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.06 | 2022 | |
| Sumitomo Pharma America, INC. | $19.80 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $18.35 | 2023 | Austedo |
| Exact Sciences Corporation | $18.14 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $17.23 | 2025 | Cobenfy |
| Dexcom, INC. | $16.82 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $16.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shonda Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.